Join
Live feed
·
PRReleasevia Quantisnow
PHAXIAM Therapeutics S.A.. logo

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

ByQuantisnow·Wall Street's wire, on your screen.
PHXM· PHAXIAM Therapeutics S.A..
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PHXM (PHAXIAM Therapeutics S.A..) and more on Quantisnow.